m9241
Recombinant proteinexperimental
Clinical trial activity
6 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
5
Phase 3
0
Phase 4
0
Earliest trial started Jan 27, 2020 (NCT04235777)
Timeline
Indications
Studied for
Mechanism of action
- Interleukin-12 subunit betaSupplementation
IL12B supplementation
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06096870 | Phase 2 | Jan 3, 2024 | National Cancer Institute (NCI) |
| NCT05361798 | Phase 2 | Dec 29, 2022 | National Cancer Institute (NCI) |
| NCT05286814 | Phase 2 | Oct 24, 2022 | National Cancer Institute (NCI) |
| NCT04633252 | Phase 1/Phase 2 (Phase 2) | Jan 8, 2021 | National Cancer Institute (NCI) |
| NCT04327986 | Phase 1/Phase 2 (Phase 2) | Apr 23, 2020 | National Cancer Institute (NCI) |
| NCT04235777 | Phase 1 | Jan 27, 2020 | National Cancer Institute (NCI) |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| National Cancer Institute (NCI) | Government | 6 | 6 | 2 | 2020 |
1 organizations
Page 1 / 1